<i>Helicobacter pylori</i> therapy for the prevention of metachronous gastric cancer

In a new study out of South Korea, researchers investigated the long-term effects of treatment to eradicate <i>Helicobacter pylori</i> on histologic improvement and the prevention of metachronous gastric cancer.

In a new study out of South Korea, researchers investigated the long-term effects of treatment to eradicate <i>Helicobacter pylori</i> on histologic improvement and the prevention of metachronous gastric cancer. Patients at a single center who had undergone endoscopic resection of early gastric cancer or high-grade adenoma were randomized to receive either <i>H. pylori</i> eradication therapy with antibiotics or placebo. With nearly 400 patients in the modified intention-to-treat analysis population, metachronous gastric cancer developed in 7.2% (14 patients) in the treatment group and in 13.4% (27 patients) in the placebo group during a median followup of 5.9 years. Furthermore, in the subgroup of 327 patients who underwent histologic analysis, improvement from baseline in the atrophy grade at the gastric corpus lesser curvature was observed in 48.4% of the patients in the treatment group and in 15.0% of those in the placebo group. There were no serious adverse effects; however, mild adverse effects were reported more often in the treatment arm than in the placebo arm.